---
title: Home brain stimulation improves walking
nct_id: NCT07518290
phase: NA
status: RECRUITING
sponsor: Shanghai University of Sport
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07518290"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07518290"
last_fetched: "2026-05-10T14:04:57.716Z"
source: "Parkinson's Pathways (curated)"
---
# Home brain stimulation improves walking

**Goal (in five words):** Home brain stimulation improves walking

**Official Title:** Remotely Supervised Home-based Transcranial Temporal Interference Stimulation on Motor Symptoms in Parkinson's Disease: Protocol For a Double Blind Randomized Controlled Trial

**Trial ID:** [NCT07518290](https://clinicaltrials.gov/study/NCT07518290)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Shanghai University of Sport
- **Target Enrollment:** 68 participants
- **Start Date:** 2026-04-04
- **Completion Date:** 2028-01-30
- **Conditions:** PARKINSON DISEASE (Disorder), Motor Symptoms
- **Interventions:** Home-based Transcranial Temporal Interference Stimulation (HB-TIS)
- **Intervention Types:** DEVICE

## Summary For Families

They're testing whether remotely supervised, home-based temporal interference brain stimulation can reduce motor symptoms like slowness, stiffness, and gait problems in people with mild-to-moderate Parkinson's. The treatment uses two high-frequency electrical currents applied through scalp electrodes that overlap inside the brain to produce a low-frequency stimulation that reaches deeper motor circuits without surgery, and sessions are done at home under remote supervision while participants keep their anti-parkinsonian medications stable. Enrollment is for people age 40 to 80 with Parkinson's at Hoehn and Yahr stages 1.5 to 3 who can walk unaided for at least 2 minutes, excluding those with DBS or metal implants, significant cognitive impairment (MoCA <21), other major neurological or orthopedic problems, or serious psychiatric illness.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinson's disease according to established clinical criteria
* Mild-to-moderate disease severity, defined as Hoehn and Yahr stage 1.5-3;
* Age between 40 and 80 years;
* Stable anti-parkinsonian medication regimen;
* Ability to walk unaided for at least 2 minutes.

Exclusion Criteria:

* contraindications to TIs (e.g., metal implantation, pacemakers, etc.);
* the use of DBS;
* significant cognitive impairment as defined by the diagnosis of Alzheimer's disease or dementia, or Montreal Cognitive Assessment (MoCA) total score\<21, a recommended threshold for dementia in PD;
* diagnosis of other neurological conditions such as multiple sclerosis, previous stroke;
* report of severe lower-extremity arthritis, pain, or orthopedic problems significantly affecting gait;
* physician-diagnosis of schizophrenia or other psychiatric illness;
* an unwillingness to cooperate or participate in the study protocol. Eligible and interested participants will then be enrolled and complete baseline assessments before the randomization.
```

## Locations (2)

- Shanghai University of Sport, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Zijun Lu — (CONTACT) — +86 21 65507862 — luzijun@snnu.edu.cn
- Shanghai University of Sport, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Zijun Lu — (CONTACT) — +86 21 65507862 — luzijun@snnu.edu.cn

## Central Contacts

- Yu Liu, Prof. — (CONTACT) — +86 21 65507351 — yuliu@sus.edu.cn
- Zijun Lu — (CONTACT) — +86 21 65507862 — luzijun@snnu.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07518290*  
*HTML version: https://parkinsonspathways.com/trial/NCT07518290*  
*Source data: https://clinicaltrials.gov/study/NCT07518290*